Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)

About this update from Viridian Therapeutics, Inc.

BEVERLY HILLS, Calif., July 16, 2026 /PRNewswire/ -- Raymond Douglas, MD, PhD , a world-renowned thyroid eye disease specialist and oculoplastic surgeon, is the first in the United States to administer LUMVOA ™ (veligrotug-vvze), an infusion therapy for thyroid eye disease (TED), post its FDA-approval. The milestone positions Dr. Douglas and his practice at the center of the next chapter in TED treatment following the FDA approval and launch of Lumvoa by Viridian Therapeutics in late June 2026.  Lumvoa is now the second FDA-approved drug for TED and is indicated for the treatment of thyroid eye disease in both active and chronic disease, giving specialists a newly approved option for a broader TED population. Lumvoa is the first approved TED treatment with labeling that includes data from both active and chronic TED, and it demonstrates statistically significant effects on diplopia response and complete resolution of diplopia in clinical studies. Thryoid eye disease (TED) is a rare autoimmune condition that can cause proptosis, diplopia, pain, soft tissue inflammation, and, in severe cases, total loss of vision. For ophthalmology and endocrinology audiences, the arrival of another approved targeted therapy is significant because TED treatment has historically relied on corticosteroids, surgery, and limited medical options for patients across different stages of disease.  "Lumvoa's approval represents an important advance for physicians treating thyroid eye disease, particularly because it expands the conversation around medical management for both active and chronic TED," said Raymond Douglas, MD, PhD. "Being first in the nation to infuse this therapy reflects my practice's commitment to bringing new, evidence-based treatment options to patients as quickly and responsibly as possible."  Dr. Douglas has long been associated with innovation in TED care and is widely recognized for his clinical and research leadership in the field. His practice focuses heavily on thyroid eye disease, and his professional profile highlights advanced medical and surgical care for patients with TED. This latest milestone reinforces the private practice's position as a TED Center of Excellence for patients seeking high-acuity TED expertise and access to newly approved therapies.  "The opportunity to help shape the field from the first TED biologic, Tepezza (teprotumumab-trbw), to this latest approval is something our entire team is dedicated to," Dr. Douglas added. "Being first to infuse Lumvoa is an extension of the work we've done for years to expand treatment options and align therapy with the needs of patients who are living with proptosis, diplopia, and other challenging manifestations of TED." 

View stock analysis, news, and events for Viridian Therapeutics, Inc.